NKp30 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of NKp30, a natural cytotoxicity receptor (NCR) expressed primarily on the surface of natural killer (NK) cells. NKp30 plays a key role in the immune system by recognizing and binding to specific ligands on target cells, facilitating the activation of NK cells and their ability to mediate cytotoxic responses. This receptor is a crucial player in the detection of abnormal cells, such as those under stress or undergoing transformation. By inhibiting NKp30, researchers can modulate the receptor's ability to engage with its ligands, providing a valuable tool for studying NK cell activation, signal transduction, and the cellular interactions that drive immune responses.
The molecular mechanism of NKp30 inhibitors generally involves interfering with the receptor's ligand-binding domain, preventing NKp30 from interacting with its specific ligands. These inhibitors may bind directly to the extracellular domain of NKp30, blocking the receptor's ability to recognize and engage with its target cells. Alternatively, some inhibitors may disrupt the receptor's downstream signaling pathways by blocking critical protein-protein interactions necessary for signal transduction. By inhibiting NKp30, researchers can explore the regulatory mechanisms that control NK cell activity, the receptor-ligand interactions that drive immune recognition, and the broader role of NKp30 in maintaining immune surveillance. This class of inhibitors is essential for dissecting the detailed molecular processes behind NK cell activation, providing insights into the immune system's ability to detect and respond to cellular abnormalities.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, affecting the signaling pathways that NCR3 is part of. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor that can affect NCR3-associated signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that can indirectly affect the downstream pathways involving NCR3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that can have an indirect effect on NCR3 function by modulating cellular metabolism and growth signals. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Tyrosine kinase inhibitor, affecting multiple signaling pathways including those involving NCR3. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits various tyrosine kinases and can thus interfere with pathways that NCR3 is a part of. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, affecting the cellular stress response mechanisms that could influence NCR3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, affecting stress responses and thus potentially influencing NCR3. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that affects protein turnover, including potentially that of NCR3. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Inhibits Akt, which is downstream of PI3K, and can therefore indirectly affect NCR3 signaling. | ||||||